Dennis D.  Kim net worth and biography

Dennis Kim Biography and Net Worth

Dr. Kim joined CymaBay in May 2021 as our Chief Medical Officer. He brings more than 20 years of drug development experience most recently serving as Chief Medical Officer of Afyx Therapeutics, where he led clinical, medical and regulatory development for Rivelin, a novel mucoadhesive patch to deliver treatment for diseases such as oral lichen planus. Prior to this, he served in senior leadership roles at Emerald Health Sciences, Zafgen, Orexigen, EnteroMedics and Amylin Pharmaceutical. He received his medical degree from The Chicago School of Medicine, completed his internal medicine residency at Rush University Medical College, and specialty fellowship training in endocrinology/metabolism at University of California, San Diego (UCSD) Medical Center. He also holds a M.B.A. with emphasis in biotechnology structure and strategy from UCSD Rady School of Business.

What is Dennis D. Kim's net worth?

The estimated net worth of Dennis D. Kim is at least $649,600.00 as of April 17th, 2023. Dr. Kim owns 20,000 shares of CymaBay Therapeutics stock worth more than $649,600 as of March 29th. This net worth approximation does not reflect any other investments that Dr. Kim may own. Learn More about Dennis D. Kim's net worth.

How do I contact Dennis D. Kim?

The corporate mailing address for Dr. Kim and other CymaBay Therapeutics executives is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. CymaBay Therapeutics can also be reached via phone at (510) 293-8800 and via email at [email protected]. Learn More on Dennis D. Kim's contact information.

Has Dennis D. Kim been buying or selling shares of CymaBay Therapeutics?

Dennis D. Kim has not been actively trading shares of CymaBay Therapeutics during the last quarter. Most recently, Dennis D. Kim sold 112,219 shares of the business's stock in a transaction on Monday, April 17th. The shares were sold at an average price of $9.54, for a transaction totalling $1,070,569.26. Following the completion of the sale, the insider now directly owns 20,000 shares of the company's stock, valued at $190,800. Learn More on Dennis D. Kim's trading history.

Who are CymaBay Therapeutics' active insiders?

CymaBay Therapeutics' insider roster includes Janet Dorling (Director), Dennis Kim (Insider), Charles McWherter (Insider), Daniel Menold (VP), Paul Quinlan (General Counsel), Sujal Shah (CEO), and Kurt von Emster (Director). Learn More on CymaBay Therapeutics' active insiders.

Are insiders buying or selling shares of CymaBay Therapeutics?

In the last year, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 600,648 shares worth more than $8,947,266.61. The most recent insider tranaction occured on February, 12th when Director Janet Dorling sold 6,000 shares worth more than $191,820.00. Insiders at CymaBay Therapeutics own 7.0% of the company. Learn More about insider trades at CymaBay Therapeutics.

Information on this page was last updated on 2/12/2024.

Dennis D. Kim Insider Trading History at CymaBay Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/17/2023Sell112,219$9.54$1,070,569.2620,000View SEC Filing Icon  
4/13/2023Sell7,781$8.98$69,873.3820,000View SEC Filing Icon  
3/28/2023Sell100$8.98$898.0020,000View SEC Filing Icon  
1/19/2022Buy20,000$3.04$60,800.00View SEC Filing Icon  
See Full Table

Dennis D. Kim Buying and Selling Activity at CymaBay Therapeutics

This chart shows Dennis D Kim's buying and selling at CymaBay Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CymaBay Therapeutics Company Overview

CymaBay Therapeutics logo
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.
Read More

Today's Range

Now: $32.48
Low: $32.48
High: $32.50

50 Day Range

MA: $29.62
Low: $22.46
High: $32.48

2 Week Range

Now: $32.48
Low: $7.26
High: $32.50

Volume

8,356,200 shs

Average Volume

4,113,430 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32